spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Drive for generics sees Korea increasingly attractive to international pharma

CPhI & P-MEC China

CPhI Korea data shows an increase in ‘overall competitiveness’

In fact, South Korean President Moon Jae-in stated in May 2019 that the Government will help foster ‘the biotechnology and pharmaceutical sectors as the country's new economic growth drive’.

Emphasizing the shift in the country’s global reputation, provisional data from the CPhI Annual Report 2019 shows that Korea improved its scores across ‘API quality’, ‘growth potential’ and ‘innovation’, with ‘overall competitiveness’ rising by 9% in the last year[i].

The new findings are announced in the lead-up to CPhI Korea  – co-organised by Informa Markets and the Korea Pharmaceutical Traders Association (KPTA) – which will open its sixth edition at the Seoul COEX Convention and Exhibition Centre from 21-23 August 2019.

“The show is widely seen as a barometer of industry trends within the region and this year we expect to see an increase in international bio buyers looking for access to services, equipment and bio-solutions as well as domestic partners. In total, over 5000 attendees from more than 50 countries and more than 190 exhibitors will attend” commented Laura Murina, Brand Manager at Informa.

Korean pharmaceutical exports have become attractive due to competitive pricing in the generics market and, as a result, Korean companies are opening more facilities overseas and using CPhI Korea to look for new international partners. In fact, the Korea Trade-Investment Promotion Agency (KOTRA) is facilitating exhibitors to meet with overseas buyers selected by the Global Bio Pharma Plaza (GBPP) at the event.

Emphasizing the international nature of Korea’s growth in exports, the CPhI Korea Conference, an integral part of the event, will include sessions from the Thai FDA, the Japanese PMDA, the China Chamber of Commerce for Imports and Exports of Medicines and Health Products (CCCMHPIE), as well as the European Directorate for the Quality of Medicines. The agenda will include detailed analysis of international regulations, GMP, QbD, and comparative strategies for global market entry.

Murina, continued: “South Korea’s expanding generics market and changing regulations are driving more international companies towards local partnerships. One of the great added benefits of this event’s size and dynamics is that it allows attendees to have more in-depth and targeted meetings. The high quality of meetings means that they deliver a very high rate of partnership outcomes.”

Finally, to help international companies looking to enter the country, CPhI Korea is working with the Korea Pharmaceutical Traders Association (KPTA) to promote a Meet the Expert Programme, which is specifically designed to help international companies understand the complexities of the South Korean market.

CPhI Korea 2019 is co-located alongside ICSE (contact service), P-MEC (pharmaceutical machinery & lab equipment), BioPh (biopharmaceuticals) and Hi (health ingredients), which along with the FDF zone, brings the entire supply chain together in one venue.
web www.cphi.com/china/
email SNIEC, Shanghai, China
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Signant Health Appoints Lawrence Miller as Chief Technology Officer

LONDON & PHILADELPHIA – June 13, 2019: Signant Health, formerly CRF Bracket, has appointed Lawrence Miller as Chief Technology Officer. Signant unites electronic Clinical Outcomes Assessment (eCOA), eConsent, Patient Engagement, Interactive Response Technology (IRT), Clinical Supply Management and Endpoint Quality into the industry’s most comprehensive patient-centric suite of technology solutions and services. An accomplished innovator, Miller brings unique vision and expertise to a Signant team already committed to advancing clinical research with its next-generation technology portfolio.
More info >>


White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

Industry Events

PPMA Total Show

1-3 October 2019, Birmingham

About PPMA Total Show PPMA Total is one of UK’s largest processing and packaging machinery exhibitions. Building on the success of the PPMA Show in 2018, PPMA Total returns to the NEC, Birmingham, on 1-3 October 2019 for another show-stopping event.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement